Skip to content

Alkermes ALKS RISPERDALCONSTA — Collaborative Arrangement Royalty Rate

Similar metrics at other companies

Biogen logo
BIIBSPINRAZA — Percentage of royalties as per collaboration
3.8%0.0pp
Protagonist Therapeutics logo
PTGXLicense And Service — Collaborative Agreement Profit Share Percentage
50%
Ionis Pharmaceuticals logo
IONSSpinraza Royalties — Revenue
$43.71M-9.0%
Ionis Pharmaceuticals logo
IONSSpinraza — Percentage Of Royalty Payments Paid On Annual Sales Of Medicine
45%0.0pp
Biogen logo
BIIBVUMERITY — Percentage of royalties as per collaboration
4%+0.3pp
Biogen logo
BIIBRITUXAN — Percentage of co promotion operating profits first fifty million
30%0.0pp

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept alks:CollaborativeArrangementRoyaltyRate.

The official record: Alkermes’s 10-K, filed February 25, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's risperdalconsta — collaborative arrangement royalty rate.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's RISPERDALCONSTA — collaborative arrangement royalty rate?
Alkermes (ALKS) reported RISPERDALCONSTA — collaborative arrangement royalty rate of 1.9% in Q4 2025.
How has Alkermes's RISPERDALCONSTA — collaborative arrangement royalty rate changed year-over-year?
Alkermes's RISPERDALCONSTA — collaborative arrangement royalty rate decreased by 0.0% year-over-year, from 1.9% to 1.9%.
What is the long-term trend for Alkermes's RISPERDALCONSTA — collaborative arrangement royalty rate?
Over 4 years (2021 to 2025), Alkermes's RISPERDALCONSTA — collaborative arrangement royalty rate has grown at a 0.0% compound annual growth rate (CAGR), from 7.5% to 7.5%.
What does RISPERDALCONSTA — collaborative arrangement royalty rate mean?
The percentage of net sales or revenue that the company is contractually obligated to pay to or receive from a partner under a collaborative arrangement for a specific product. This rate serves as a primary indicator of the economic value sharing between the company and its collaborators. It directly impacts the profitability of the product segment by dictating the margin retained after royalty obligations.